These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38198333)

  • 1. [Variability in Drug Procurement within Group 1B of the Pharmaceutical Specialized Scheme in Brazil].
    Rossignoli P; Pontarolo R; Fernandez-Llimos F
    Cien Saude Colet; 2024 Jan; 29(1):e18142022. PubMed ID: 38198333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
    Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
    Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Federal procurement of unlicensed medicines in Brazil; findings and implications.
    Teodoro CRDS; Caetano R; Godman B; Dos Reis ALA; Maia AA; Ramos MCB; Osorio-de-Castro CGS
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):607-613. PubMed ID: 28330384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011.
    Luo J; Oliveira MA; Ramos MB; Maia A; Osorio-de-Castro CG
    BMC Public Health; 2014 Apr; 14():367. PubMed ID: 24735589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019.
    Dos Santos RLB; Pepe VLE; Osorio-de-Castro CGS
    BMC Cancer; 2022 Jul; 22(1):769. PubMed ID: 35840933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drivers of federal spending in pharmaceuticals of the Specialized Component: measurement and analysis.
    Vieira FS
    Rev Saude Publica; 2021; 55():91. PubMed ID: 34910025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia's Social Health Insurance System.
    Anggriani Y; Ramadaniati HU; Sarnianto P; Pontoan J; Suryawati S
    Value Health Reg Issues; 2020 May; 21():1-8. PubMed ID: 31634791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between provincial income levels and drug prices in China over the period 2010-2017.
    Shi W; Wouters OJ; Liu G; Mossialos E; Yang X
    Soc Sci Med; 2020 Oct; 263():113247. PubMed ID: 32799026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
    Long H; Yang Y; Geng X; Mao Z; Mao Z
    Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
    Wouters OJ; Sandberg DM; Pillay A; Kanavos PG
    Soc Sci Med; 2019 Jan; 220():362-370. PubMed ID: 30513486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resource allocation for pharmaceutical procurement in the Brazilian Unified Health System.
    Vieira FS; Zucchi P
    Rev Saude Publica; 2011 Oct; 45(5):906-13. PubMed ID: 21808832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
    Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hipoglicemiantes Orais Para Diabetes Mellitus Tipo 2: Comparação de Preços no Brasil e em Outros Sistemas Universais de Saúde.
    de Oliveira GLA; Izidoro JB; Ferré F; E Sousa SRA; Acurcio FA
    Value Health Reg Issues; 2018 Dec; 17():135-141. PubMed ID: 29935411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation in restorative treatments in public health: a 10-year analysis of resin composite procurement in Brazil.
    Balbinot GS; Celeste RK; Leitune VCB; Collares FM
    Cad Saude Publica; 2022; 38(3):e00118321. PubMed ID: 35416893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
    Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
    Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014.
    Hamzah NM; Perera PN; Rannan-Eliya RP
    BMC Health Serv Res; 2020 Jun; 20(1):509. PubMed ID: 32503539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.